Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies

Table 2

The GLMM results on the yang-xu, yin-xu, and yu zhengs.

	Yang-xu zheng			Yin xu zheng			Yu zheng
	Estimate	SE	P	Estimate	SE	P	Estimate	SE	P
Intercept	8.39	3.28	0.01	6.64	2.26	<0.01	9.84	2.85	<0.01
Target therapy stage^a	0.33	1.50	0.83	0.89	1.10	0.42	0.81	1.31	0.54
Combined therapy stage^a	3.88	1.44	0.01	2.55	1.08	0.02	2.40	1.25	0.06
3 months after treatment^b	3.65	0.78	<0.01	2.83	0.67	<0.01	2.36	0.67	<0.01
1 month after treatment^b	2.32	0.66	<0.01	2.45	0.54	<0.01	2.05	0.60	<0.01
Age	0.03	0.06	0.60	−0.02	0.04	0.69	0.00	0.05	0.95
Diabetes	1.95	2.17	0.37	1.08	1.62	0.51	2.37	1.88	0.21
Coronary heart disease	3.35	2.14	0.12	5.07	1.58	<0.01	3.37	1.86	0.07
Cancer stage III or IV	0.51	1.28	0.69	0.46	0.92	0.62	0.61	1.11	0.59
TCM Treatment^c	1.93	1.13	0.09	0.95	0.90	0.29	1.17	1.00	0.24
Mastectomy^d	−2.89	1.82	0.11				−3.38	1.58	0.04

aAnthracycline-based chemotherapy, ^bpretreatment, ^cwithout TCM treatment, and ^dwithout mastectomy.
GLMM: generalized linear mixed model, AR(1). The significance level was set at P < 0.05.